# Dry Age-Related Macular Degeneration AMD Market > Global Dry Age-Related Macular Degeneration Market Research Report Information By Stages (Early Age-Related Macular Degeneration, Intermediate Age-Related Macular Degeneration, and Late Age-Related Macular Degeneration), By Age Group (Above 75 Years, Above 60 Years, and Above 40 Years), By Diagnosis and Treatment (Treatment and Diagnosis), By Route of Administration (Oral and Injectables), By End Users (Hospitals & Clinics, Diagnostic Centers, and Academic & Research Institutes) and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth & Industry Forecast 2025 To 2035. - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.3% - **2024:** $ 4.76 Billion - **2025:** $ 5.16 Billion - **2035:** $ 11.44 Billion - **Key Players:** Regeneron Pharmaceuticals (US), Novartis (CH), Roche(CH), Bayer (DE), Apellis Pharmaceuticals (US), Horizon Therapeutics (IE), Santen Pharmaceutical (JP), Alcon (CH), Zeiss (DE) **Report ID:** MRFR/LS/9174-CR · **Pages:** 171 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/dry-age-related-macular-degeneration-amd-market-10657 --- ## Market Summary ## **Dry Age-Related Macular Degeneration Market Overview** Dry Age-Related Macular Degeneration Market Valued at USD 4.4 billion in 2023, projected to grow from USD 4.8 billion in 2024 to USD 8.61 billion by 2032, exhibiting a CAGR of 8.30% during the forecast period (2023 - 2032).  Increasing geriatric populations and increasing prevalence of age-related macular degeneration are among the factors responsible for the growth of the dry AMD market. Additionally, novel treatments for dry AMD have been developed, and a growing number of clinical trials focusing on dry AMD have been conducted, which are the key market drivers spurs the market growth. Source Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **Dry Age-Related Macular Degeneration Market Trends** Despite an increasing life expectancy and decreasing fertility levels, the older population in the world is growing rapidly, according to a UN report published in December 2020. In 2020, 727 million people were 65 or older, and the number is predicted to rise to 1.5 billion by 2050, according to the same report. There is a projected increase in the proportion of people aged 65 and over in the population from 9.3% in 2020 to 16.0% in 2050. The same is predicted in China. The UN projects a rise in the share of seniors from 12% in 2020 to 26% by 2050. To support national and international health goals, comprehensive and comparable health spending estimates are crucial to health policy and planning. On February 20, 2019, the World Health Organization (WHO) released a new report on health expenditure, indicating that  health spending increased by 6% in low- and middle-income countries and 4% in high-income countries. There is a shift in how external and domestic funding is used, but in middle-income countries, external funding is declining. Governments spend less than 40% on primary health care. Only a few medications, primarily anti-VEGFs, are approved to treat age-related macular degeneration. Anti-VEGF drugs require repeated and inconvenient intraocular injections, which makes treatment more burdensome and results in non-adherence. It is being developed by companies to develop longer-acting anti-VEGFs and vitreous implants to facilitate sustained drug delivery to overcome this obstacle. It is expected that long-acting anti-VEGF drugs such as Beovu and Vabysmo will propel market growth in the coming years. Still, the entry of biosimilars and a high adoption rate of off-label drugs like impede market growth.  However, the FDA approved a biosimilar version under the brand name BYOOVIZ in September 2021 for treating wet AMD, myopic choroidal neovascularization, and [retinal vein occlusion](../../../reports/retinal-vein-occlusion-market-5377) in the United States. This is another factor driving the growth of the dry age-related macular degeneration market revenue. ## **Dry Age-Related Macular Degeneration Market Segment Insights** ### **Dry Age-Related Macular Degeneration Stages Insights** The dry age-related macular degeneration market segmentation, based on stages, includes early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. The early age-related macular degeneration segment held the majority share in 2021, contributing to around ~35-37% with respect to the dry [age-related macular degeneration market](../../../reports/age-related-macular-degeneration-market-5736) revenue. As AMD patient numbers increase at this stage, it is difficult to distinguish between early-stage AMD and later-stage AMD. Early-stage AMD does not result in vision loss and is diagnosed by the presence of medium-sized drusen beneath the retina. The drusen are deposits of amorphous debris that form near the retinal pigment epithelium's basement membrane. ### **Dry Age-Related Macular Degeneration Age Group Insights** The dry age-related macular degeneration market segmentation, based on age group, includes above 75 years, above 60 years, and above 40 years. The above 75 years segment dominated the dry age-related macular degeneration market in 2021 and is projected to be the faster-growing segment during the forecast period, 2023-2032. In the elderly, vision loss is a serious problem since it gets worse over time.  There are two primary types of macular degeneration dry macular degeneration and wet macular degeneration. Both are potentially fatal and require medical attention, which is why there is an increasing number of elderly patients in the dry age-related macular degeneration market growth. ### **Dry Age-Related Macular Degeneration Route of Administration Insights** The dry age-related macular degeneration market data has been bifurcated by route of administration into oral and injectables. The oral segment dominated the dry age-related macular degeneration market in 2021 and is projected to be the faster-growing segment during the forecast period, 2023-2032. Nutrition therapy is prescribed as the main preventative measure for dry age-related macular degeneration. Zinc, copper, beta-carotenoids, and other antioxidants are prescribed. Because most of the clinical studies have used this route of administration, it holds the largest share of the dry age-related macular degeneration market. **Figure 2  Dry Age-Related Macular Degeneration Market, by Route of Administration, 2022 & 2032 (USD Billion)** **_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_** ### **Dry Age-Related Macular Degeneration End User Insights** Based on end users, the dry age-related macular degeneration industry has been segmented into hospitals & clinics, diagnostic centers, and academic & research institutes. Hospitals & clinics held the largest segment share in 2021. As an increasing number of patients are being monitored for eye diseases, this share is primarily attributed to the fact that hospitals are equipped with advanced and complete treatments. Hence, patients generally prefer to go there for care. Clinics are also medical centers that treat AMD patients. ### **Dry Age-Related Macular Degeneration Regional Insights** By Region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American dry age-related macular degeneration market accounted for USD 3.58 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. There is an increase in dry age-related macular degeneration prevalence as people age, reaching its peak between the ages of 80 and 89. Government initiatives and funding are also propelling the growth of this market in North America. Further, the major countries studied in the dry age-related macular degeneration market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 3****Dry Age-Related Macular Degeneration Market Share by Region 2022 (%)** **** **_Source Secondary Research, Primary Research, MRFR Database and Analyst Review_** Europe's dry age-related macular degeneration market accounts for the second-largest market share. As a result of an increasingly older population and an increasing patient population, the dry age-related macular degeneration market in Europe is growing due to improved government initiatives, increasing healthcare frames, and a growing demand for technologically advanced treatments. Further, the German dry age-related macular degeneration market held the largest market share, and the UK dry age-related macular degeneration market was the fastest-growing market in the European region The Asia-Pacific dry age-related macular degeneration market is expected to grow at the fastest CAGR from 2023 to 2032. The dry age-related macular degeneration AMD market is expected to grow as the prevalence of eye diseases rises, healthcare expenditures rise, and multinational companies establish operations in emerging countries. Moreover, the China dry age-related macular degeneration market held the largest market share, and the India dry age-related macular degeneration market was the fastest-growing market in the Asia-Pacific region **Dry Age-Related Macular Degeneration Key Market Players & Competitive Insights** Major market players are spending a lot of money on R&D to increase their product lines, which will help the dry age-related macular degeneration market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the dry age-related macular degeneration industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment. One of the primary business strategies adopted by manufacturers in the dry age-related macular degeneration industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. The dry age-related macular degeneration industry has provided medicine with some of the most significant benefits in recent years. In the dry age-related macular degeneration market, major players such as Santen Pharmaceuticals Inc. (Japan), Allergan plc (Ireland), Bausch Health (Canada), Alimera Science Inc. (US), and others are working on expanding the market demand by investing in research and development activities. Biopharmaceutical company Alimera Sciences Inc. develops, manufactures, and sells prescription [ophthalmic](../../../reports/ophthalmic-suspension-market-4350) pharmaceuticals to treat eye diseases. Alimera Sciences focuses exclusively on eye diseases affecting the back of the eye. In April 2021, Ocumension Therapeutics was licensed by Alimera to commercialize ophthalmology medicine in Asia and China under an exclusive license agreement. The deal was worth USD 20 million, of which 10 million was paid upfront, and the rest would be based on product sales. Also, A leading pharmaceutical company, Bausch Health Companies Inc., discovers and distributes a variety of products, such as contact lenses, intraocular lenses, ophthalmic surgical equipment, aesthetic devices, and drugs for unmet medical needs in central nervous system disorders, eye health, and gastrointestinal diseases. Bausch Health Companies serves customers around the world. **Key Companies in the Dry Age-Related Macular Degeneration market include** **Dry Age-Related Macular Degeneration Industry Developments** **July 2020** The bioMérieux company has launched BIOFIRE MYCOPLASMA, a test for detecting mycoplasma in pharmaceutical products used in biotherapeutics (antibodies, hormones, cell and gene therapies, etc.) - one of the most active sectors in the pharmaceutical industry. Some countries in Europe and Asia-Pacific will launch the BIOFIRE MYCOPLASMA test in the near future. It is currently available in the US. **March 2020** Zimura (avacincaptad pegol), an inhibitor of complement C5, has been granted Fast Track designation by the FDA in the development of treatments for geographic atrophy (GA) due to dry age-related macular degeneration (AMD). ## **Dry Age-Related Macular Degeneration Market Segmentation** ### **Dry Age-Related Macular Degeneration Stages Outlook** ### **Dry Age-Related Macular Degeneration Age Group Outlook** ### **Dry Age-Related Macular Degeneration Diagnosis and Treatment Outlook** ### **Dry Age-Related Macular Degeneration Route of Administration Outlook** ### **Dry Age-Related Macular Degeneration End Users Outlook** ### **Dry Age-Related Macular Degeneration Regional Outlook** ## Market Drivers ### Increased Awareness and Education Increased awareness and education regarding Dry Age-Related Macular Degeneration are pivotal in shaping the Dry Age-Related Macular Degeneration Market. Public health campaigns and educational initiatives have been instrumental in informing individuals about the risk factors and symptoms associated with AMD. As awareness grows, more individuals are likely to seek early diagnosis and treatment, which can lead to better management of the disease. This heightened awareness is expected to drive demand for screening and therapeutic options, thereby fostering growth within the market. Additionally, healthcare providers are increasingly emphasizing the importance of regular eye examinations, further contributing to the expansion of the Dry Age-Related Macular Degeneration Market. ### Government Initiatives and Funding Government initiatives and funding aimed at addressing eye health are vital drivers for the Dry Age-Related Macular Degeneration Market. Various health organizations and governmental bodies are increasingly recognizing the burden of AMD on public health. As a result, they are allocating resources to support research, awareness campaigns, and access to treatment. For instance, funding for clinical trials and public health initiatives can significantly enhance the understanding and management of AMD. Such support not only fosters innovation but also encourages collaboration among stakeholders, including researchers, healthcare providers, and patients. This collaborative approach is likely to stimulate growth and development within the Dry Age-Related Macular Degeneration Market. ### Advancements in Research and Development Ongoing advancements in research and development are crucial for the Dry Age-Related Macular Degeneration Market. Innovative therapies, including gene therapy and stem cell treatments, are being explored to address the underlying causes of AMD. The market has witnessed a surge in clinical trials aimed at evaluating the efficacy of new treatment modalities. For instance, recent studies have indicated that certain pharmacological agents may slow the progression of dry AMD, enhancing the quality of life for patients. The commitment of pharmaceutical companies to invest in R&D is likely to yield novel solutions, thereby expanding the treatment landscape and driving market growth in the Dry Age-Related Macular Degeneration Market. ### Technological Innovations in Treatment Delivery Technological innovations in treatment delivery are transforming the Dry Age-Related Macular Degeneration Market. The integration of telemedicine and digital health solutions is enhancing patient access to care and facilitating remote monitoring of AMD. These advancements allow for timely interventions and personalized treatment plans, which are essential for managing the disease effectively. Moreover, the development of advanced imaging techniques, such as optical coherence tomography, enables healthcare professionals to diagnose and monitor AMD with greater precision. As technology continues to evolve, it is likely to play a significant role in improving patient outcomes and driving growth in the Dry Age-Related Macular Degeneration Market. ### Rising Prevalence of Dry Age-Related Macular Degeneration The increasing prevalence of Dry Age-Related Macular Degeneration (AMD) is a primary driver for the Dry Age-Related Macular Degeneration Market. As populations age, the incidence of AMD is expected to rise significantly. According to recent estimates, nearly 196 million individuals are projected to be affected by AMD by 2020, with numbers expected to reach 288 million by 2040. This growing patient population necessitates the development and availability of effective treatment options, thereby propelling market growth. Furthermore, the aging demographic is likely to increase the demand for healthcare services and interventions aimed at managing AMD, which in turn stimulates investment in research and development within the Dry Age-Related Macular Degeneration Market. ## Future Outlook The Dry Age-Related Macular Degeneration Market is projected to grow at an 8.3% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of telemedicine platforms for remote patient monitoring - Investment in [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) research for AMD treatment - Expansion of personalized nutrition products targeting eye health By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient awareness. ## Segment Insights ### By Stages: Intermediate Age-Related Macular Degeneration (Largest) vs. Late Age-Related Macular Degeneration (Fastest-Growing) In the Dry Age-Related Macular Degeneration Market, the distribution of market share among different stages reveals that Intermediate Age-Related Macular Degeneration holds the largest segment. This stage is characterized by the presence of drusen, which impacts visual acuity and is a significant concern for individuals. In contrast, Late Age-Related Macular Degeneration, while smaller in current market share, is recognized as the fastest-growing segment as more patients are diagnosed and treatment options expand. The increase in awareness and advancements in treatment regimens are influencing this dynamics. Intermediate Age-Related Macular Degeneration (Dominant) vs. Late Age-Related Macular Degeneration (Emerging) Intermediate Age-Related Macular Degeneration is viewed as the dominant segment within this market, significantly influencing treatment strategies and healthcare priorities. Characterized by noticeable visual changes due to the accumulation of drusen, this stage is pivotal for early intervention. In contrast, Late Age-Related Macular Degeneration is the emerging segment, attracting increasing attention due to its implications on severe vision loss. This segment's growth is propelled by ongoing research into novel therapies and increasing case incidences, ultimately urging the development of focused treatment protocols and patient management strategies. The interplay between these stages shapes the overall market landscape. ### By Age Group: Above 75 Years (Largest) vs. Above 60 Years (Fastest-Growing) In the Dry Age-Related Macular Degeneration Market, the age group of above 75 years holds the largest market share, driven by the higher prevalence of age-related macular degeneration in this demographic. Reports indicate that individuals in this age bracket are experiencing significant vision-related challenges, making them a primary target for treatment solutions. On the other hand, the age group above 60 years is rapidly gaining attention due to stabilizing healthcare access and increased awareness about eye health, making it one of the fastest-growing segments in this market. Above 75 Years (Dominant) vs. Above 60 Years (Emerging) The above 75 years segment represents the dominant demographic in the Dry Age-Related Macular Degeneration market, showcasing a greater vulnerability to dry AMD due to aging-related factors. This group often requires advanced treatment options tailored to their specific needs, driving innovation in therapeutic strategies. In contrast, the above 60 years segment is emerging as a critical market player, propelled by a proactive approach to eye health and a greater inclination towards preventive care. This younger bracket is increasingly engaging with healthcare services, promoting early diagnosis and intervention, indicating a shift in the market dynamics as awareness grows. ### By Route of Administration: Injectables (Largest) vs. Oral (Fastest-Growing) In the Dry Age-Related Macular Degeneration Market, the distribution of market share among the routes of administration shows that injectables currently hold the dominant position, reflecting their effectiveness and preference among healthcare providers. These injectable treatments are often preferred for their targeted delivery and efficiency in managing the condition, contributing to their larger share in the market. Meanwhile, oral medications are gaining traction as the fastest-growing segment, appealing to patients who prefer easier administration and fewer visits to healthcare facilities. Injectables (Dominant) vs. Oral (Emerging) Injectables are the dominant route of administration in the Dry Age-Related Macular Degeneration Market due to their precise delivery and rapid action in treatment. These therapies typically involve administering medications directly into the eye or systemic circulation, resulting in higher efficacy for conditions like dry AMD. Conversely, oral medications represent an emerging route, characterized by convenience and patient compliance. This segment is witnessing growth as advancements in formulation are making oral treatments more effective, thus enticing patients preferring less invasive options. Providers are increasingly optimistic about the oral route's potential to expand market access and enhance adherence to treatment regimes. ### By End Users: Hospitals & Clinics (Largest) vs. Diagnostic Centers (Fastest-Growing) The 'End Users' segment in the Dry Age-Related Macular Degeneration Market is primarily composed of Hospitals & Clinics, Diagnostic Centers, and Academic & Research Institutes. Among these, Hospitals & Clinics hold the largest market share due to their extensive patient base and the ability to provide comprehensive care, including diagnosis and treatment. Conversely, Diagnostic Centers are experiencing rapid growth fueled by increasing awareness of eye health and early diagnosis, serving as specialized establishments that focus on advanced diagnostic procedures. Hospitals & Clinics (Dominant) vs. Diagnostic Centers (Emerging) Hospitals & Clinics are the dominant players in the Dry Age-Related Macular Degeneration Market, showcasing a robust infrastructure equipped with advanced medical technologies and experienced professionals for effective patient management. They offer a broad spectrum of services, including innovative treatments and follow-up care, contributing to their strong hold on the market. On the other hand, Diagnostic Centers represent an emerging segment characterized by their focus on precision diagnostics and innovative testing methods. With rising investments aimed at enhancing diagnostic capabilities and technology adoption, these centers are increasingly important in the overall treatment landscape, aiming to bridge the gap between timely diagnosis and treatment initiation. ## Regional Market Share Analysis By Region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American dry age-related macular degeneration market accounted for USD 3.58 billion in 2021 and is expected to exhibit a significant CAGR growth during the study period. There is an increase in dry age-related macular degeneration prevalence as people age, reaching its peak between the ages of 80 and 89. Government initiatives and funding are also propelling the growth of this market in North America. Further, the major countries studied in the dry age-related macular degeneration market report are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 3 Dry Age-Related Macular Degeneration Market Share by Region 2022 (%)** _**Source Secondary Research, Primary Research, MRFR Database and Analyst Review**_ Europe's dry age-related macular degeneration market accounts for the second-largest market share. As a result of an increasingly older population and an increasing patient population, the dry age-related macular degeneration market in Europe is growing due to improved government initiatives, increasing healthcare frames, and a growing demand for technologically advanced treatments. Further, the German dry age-related macular degeneration market held the largest market share, and the UK dry age-related macular degeneration market was the fastest-growing market in the European region The Asia-Pacific dry age-related macular degeneration market is expected to grow at the fastest CAGR from 2023 to 2032. The dry age-related macular degeneration AMD market is expected to grow as the prevalence of eye diseases rises, healthcare expenditures rise, and multinational companies establish operations in emerging countries. Moreover, the China dry age-related macular degeneration market held the largest market share, and the India dry age-related macular degeneration market was the fastest-growing market in the Asia-Pacific region ## Competitive Benchmarking Major market players are spending a lot of money on R&D to increase their product lines, which will help the dry age-related macular degeneration market grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the dry age-related macular degeneration industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment. One of the primary business strategies adopted by manufacturers in the dry age-related macular degeneration industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. The dry age-related macular degeneration industry has provided medicine with some of the most significant benefits in recent years. In the dry age-related macular degeneration market, major players such as Santen Pharmaceuticals Inc. (Japan), Allergan plc (Ireland), Bausch Health (Canada), Alimera Science Inc. (US), and others are working on expanding the market demand by investing in research and development activities. Biopharmaceutical company Alimera Sciences Inc. develops, manufactures, and sells prescription ophthalmic pharmaceuticals to treat eye diseases. Alimera Sciences focuses exclusively on eye diseases affecting the back of the eye. In April Ocumension Therapeutics was licensed by Alimera to commercialize ophthalmology medicine in Asia and China under an exclusive license agreement. The deal was worth USD 20 million, of which 10 million was paid upfront, and the rest would be based on product sales. Also, A leading pharmaceutical company, Bausch Health Companies Inc., discovers and distributes a variety of products, such as contact lenses, intraocular lenses, ophthalmic surgical equipment, aesthetic devices, and drugs for unmet medical needs in central nervous system disorders, eye health, and gastrointestinal diseases. Bausch Health Companies serves customers around the world. ## Recent News & Developments **July 2020** The bioMérieux company has launched BIOFIRE MYCOPLASMA, a test for detecting mycoplasma in pharmaceutical products used in biotherapeutics (antibodies, hormones, cell and gene therapies, etc.) - one of the most active sectors in the pharmaceutical industry. Some countries in Europe and Asia-Pacific will launch the BIOFIRE MYCOPLASMA test in the near future. It is currently available in the US. **March 2020** Zimura (avacincaptad pegol), an inhibitor of complement C5, has been granted Fast Track designation by the FDA in the development of treatments for geographic atrophy (GA) due to dry age-related macular degeneration (AMD). ## Report Scope | MARKET SIZE 2024 | 4.76(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 5.155(USD Billion) | | MARKET SIZE 2035 | 11.44(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.3% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Apellis Pharmaceuticals (US), Horizon Therapeutics (IE), Santen Pharmaceutical (JP), Alcon (CH), Zeiss (DE) | | Segments Covered | Stages, Age Group, Diagnosis and Treatment, Route of Administration, End Users, Region | | Key Market Opportunities | Advancements in gene therapy and digital health solutions enhance treatment options in the Dry Age-Related Macular Degeneration Market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Dry Age-Related Macular Degeneration Market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation for the Dry Age-Related Macular Degeneration Market in 2035?** A: The projected market valuation for the Dry Age-Related Macular Degeneration Market in 2035 is 11.44 USD Billion. **Q: What was the market valuation for the Dry Age-Related Macular Degeneration Market in 2024?** A: The market valuation for the Dry Age-Related Macular Degeneration Market in 2024 was 4.76 USD Billion. **Q: What is the expected CAGR for the Dry Age-Related Macular Degeneration Market from 2025 to 2035?** A: The expected CAGR for the Dry Age-Related Macular Degeneration Market during the forecast period 2025 - 2035 is 8.3%. **Q: Which age group shows the highest market valuation for Dry Age-Related Macular Degeneration?** A: The age group above 75 years shows the highest market valuation, projected at 4.5 USD Billion. **Q: What are the key segments of the Dry Age-Related Macular Degeneration Market?** A: Key segments include stages of the disease, age groups, routes of administration, and end users. **Q: Which route of administration is expected to have the highest market valuation?** A: Injectables are expected to have the highest market valuation, projected at 6.94 USD Billion. **Q: Who are the leading companies in the Dry Age-Related Macular Degeneration Market?** A: Leading companies include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, and Apellis Pharmaceuticals. **Q: What is the projected market valuation for Intermediate Age-Related Macular Degeneration in 2035?** A: The projected market valuation for Intermediate Age-Related Macular Degeneration in 2035 is 5.56 USD Billion. **Q: How does the market valuation for Late Age-Related Macular Degeneration compare to Early Age-Related Macular Degeneration?** A: In 2035, Late Age-Related Macular Degeneration is projected at 2.52 USD Billion, compared to 3.36 USD Billion for Early Age-Related Macular Degeneration. **Q: What is the expected market valuation for hospitals and clinics as end users in 2035?** A: The expected market valuation for hospitals and clinics as end users in 2035 is 4.5 USD Billion. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/dry-age-related-macular-degeneration-amd-market-10657*